T2	total-participants 1134 1137	160
T3	control-participants 1162 1164	92
T4	intervention-participants 1194 1196	42
T5	intervention 215 261	trastuzumab and pertuzumab ± weekly paclitaxel
T6	outcome 1408 1416	pCR rate
T7	iv-bin-percent 1442 1447	90.5%
T8	cv-bin-percent 1463 1468	36.3%
T9	outcome 1541 1555	non-responders
T10	outcome 1567 1575	pCR rate
T11	cv-bin-abs 1516 1518	24
T12	control-participants 1519 1521	92
T13	cv-bin-percent 1585 1589	8.3%
T14	iv-bin-percent 1604 1609	44.7%
T15	iv-bin-abs 1625 1627	38
T16	intervention-participants 1628 1630	92
T17	iv-bin-percent 1636 1641	42.9%
T18	iv-bin-abs 1688 1690	30
T19	intervention-participants 1691 1693	92
T20	outcome 1613 1623	responders
T21	outcome 1659 1686	unclassified early response
T1	eligibility 678 717	Female patients with HER2+/HR- EBC (M0)
T22	control 1184 1189	T + P
